VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (4)
Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer.
Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma.
Symptom burden of cancer patients: validation of the German M. D. Anderson Symptom Inventory: a cross-sectional multicenter study.
Transcriptional regulation of renal dopamine D1 receptors in hypertension during
See All 4 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer.
Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer. Ann N Y Acad Sci. 2022 02; 1508(1):35-53.
View in:
PubMed
subject areas
Biomarkers, Tumor
Carcinogenesis
Epithelial-Mesenchymal Transition
Female
Gangliosides
Humans
Neoplastic Stem Cells
Triple Negative Breast Neoplasms
authors with profiles
MICHAEL ANDREEFF
VENKATA LOKESH BATTULA